Progyny (Progyny) Additional Paid-In Capital

: $462 Mil(As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Progyny's quarterly additional paid-in capital increased from Jun. 2023 ($409 Mil) to Sep. 2023 ($438 Mil) and increased from Sep. 2023 ($438 Mil) to Dec. 2023 ($462 Mil).

Progyny's annual additional paid-in capital increased from Dec. 2021 ($255 Mil) to Dec. 2022 ($350 Mil) and increased from Dec. 2022 ($350 Mil) to Dec. 2023 ($462 Mil).

Progyny Additional Paid-In Capital Historical Data

The historical data trend for Progyny's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progyny Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

228.76

236.14

255.34

349.53

461.64

Progyny Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															349.53	379.07	408.81	438.04	461.64

Progyny Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Progyny Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Progyny's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Progyny (Progyny) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Progyny Inc (NAS:PGNY) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1359 Broadway, New York, NY, USA, 10018

Website

https://www.progyny.com

Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.

Executives

David J Schlanger	director, officer: Executive Chairman	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Michael E Sturmer	officer: President	48 LEDYARD RD, WEST HARTFORD CT 06117
Mark S. Livingston	officer: Chief Financial Officer	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK NY 10018
Kevin K Gordon	director	155 S LIMERICK RD, LIMERICK PA 19468
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Peter Anevski	officer: Chief Executive Officer	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Cheryl Scott	director	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Norman Payson	director	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Allison Swartz	officer: EVP, GC	C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Lloyd H Dean	director	185 BERRY STREET, SUITE 300, SAN FRANCISCO CA 94107
Monice Barbero	officer: EVP, GC and Secretary	C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Beth C Seidenberg	director
Jennifer Bealer	officer: EVP, General Counsel	C/O PROGYNY, INC., 245 5TH AVENUE, NEW YORK NY 10016
Malissia Clinton	director	333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730